WHO prequalifies first products manufactured in Egypt
WHO prequalifies first products manufactured in Egypt
Today WHO prequalified two products manufactured by the Egyptian Pharmaceutical Industry Co. (EIPICO): ceftriaxone, 1 gm/vial (HA479) and ceftriaxone, 500 mg/vial powder for injection (HA480). These two products ― antibiotics for use in treating HIV/AIDS-related conditions in adults, adolescents and children ― are the first products manufactured in Egypt to be prequalified, and are now eligible for procurement by international donors. They represent Egypt's potential as a producer of quality-assured medicines for priority diseases.
WHO has been providing technical support to manufacturers and national regulatory authorities in the WHO Eastern Mediterranean region since 2008, to improve medicines manufacture and regulation. Prequalification of the two EIPICO products follows prequalification of three antimalarials (amodiaquine + artesunate tablets: MA056, MA057 and MA058) manufactured by Maphar Laboratories in Morocco.
There are approximately 116 finished pharmaceutical product (FPP) manufacturers in Egypt. The Egyptian Government plans to increase investment in the sector and to expand the production capacity and quality standards of the country's manufacturers. In view of this government support, it is anticipated that more Egyptian FPP manufacturers will apply for WHO prequalification. Several manufacturers in the Eastern Mediterranean region (in Egypt, Iran, Jordan, Pakistan and Oman) are already actively pursuing prequalification of their FPPs.
-
HA479: Ceftriaxone (as sodium) - 1g - Powder for injection - Egyptian International Pharmaceutical Industries Co
EIPICO - EGYPT -
HA480: Ceftriaxone (as sodium) - 0.5g - Powder for injection - Egyptian International Pharmaceutical Industries Co
EIPICO - EGYPT